No Stock Yet
Opinion | Hong Kong stocks are currently in a “hovering period” in a bull market! What are the signs that the market is starting? What are the industry allocation strategies?
In the “hovering period” of the Hong Kong stock bull market, institutions suggest continuing to focus on the “three arrows” and configure “performance improvement” + “high dividend strategy”.
Looking back over the past decade, what was the market performance before and after the Central Economic work Conference?
The investment promotion strategy predicts that the Central Economic work Conference in December will have more clear measures to stabilize growth in the areas of stable real estate, traditional infrastructure, medical infrastructure and new digital infrastructure, so that the market is expected to further enhance the impact of China's economy coming out of the epidemic next year.
Shenzhen: recruiting municipal industrial innovation centers for biomedicine, high-end medical devices and large health industries
Pharmaceutical stocks continue to rise! Organization: optimistic about health care recovery, while suggesting to focus on innovative drugs and investment opportunities at the bottom of the CXO plate
On November 16, Hong Kong pharmaceutical stocks continued to rise, with Rongchang biology, Alibaba Health Information Technology, JD Health, clover biology, Kangfang biology and so on rising one after another.
Galaxy Securities: collective Mining Policy affects Market sentiment the overall valuation of the pharmaceutical sector is still low
Seven departments: stars are not allowed to endorse tobacco and tobacco products (including e-cigarettes), out-of-school training, medical, pharmaceutical, medical devices, health food and formula food for special medical purposes.
Looking at the investment opportunities in the field of interventional treatment of structural heart disease from the listing of 2291.HK in Hong Kong
Lepu Xintai Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Xintai Medical", stock code: 2291.HK), is conducting a public offering in Hong Kong.
The pharmaceutical sector continues to rise! The trend of public offering to adjust the position has also been exposed, the leading stock of medicine has been increased, how to lay out next?
The pharmaceutical sector has continued to rebound recently, what is the situation of public offering funds adjusting their positions? The fund's three-quarter report, which was disclosed on October 26th, gives the answer.
State Drug Administration: full implementation of electronic registration certificate for medical devices from November 1
A new type of vascular interventional device "drug-coated balloon" high growth suggestion to pay attention to Blue Sail Medical (002382.SZ), etc.
According to a research report released by Cinda Securities, Swiss medical technology company MedAlliance announced on October 18 that it had reached an acquisition agreement with Cordis, which demonstrates market confidence in the future development of rapamycin drug balloons, Zhitong Financial APP learned. As a new type of vascular interventional device, drug-coated balloon has many advantages, such as no foreign body implantation, no risk of in-stent thrombosis, treatment of special lesions and so on. With the improvement of market recognition of clinical value of drug-coated balloon, it is expected that the scale of domestic drug-coated balloon market will maintain rapid growth. The bank believes that painstaking efforts
No Stock Yet